Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...

The Food and Drug Administration is cracking down on copycat versions of Ozempic — the brand name of semaglutide — and ...

The FDA is cracking down on off brand weight loss products similar to Ozempic. GLP-1 drugs for weight loss like Wegovy or ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

A media representative for the FDA told NJBIZ the agency does not comment on litigation. Under U.S. regulations ... manufacturing capacity of Wegovy and Ozempic. The Danish drugmaker has its ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

On February 21, 2025, the FDA updated its drug shortage list and labeled the shortage of all doses of injectable semaglutide (Ozempic/Wegovy ... compliant with FDA regulations and appropriately ...